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ABSTRACT
Background: Several potential predictive markers of efficacy of targeted agents 
in patients with metastatic renal cell carcinoma (mRCC) have been identified. 
Interindividual heterogeneity warrants further investigation.
Patients and methods: Multicenter, observational, retrospective study in 
patients with clear-cell mRCC treated with sunitinib. Patients were classified in two 
groups: long-term responders (LR) (progression-free survival (PFS)≥22 months and 
at least stable disease), and primary refractory (PR) (progressive disease within 
3-months of sunitinib onset). Objectives were to compare baseline clinical factors in 
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both populations and to correlate tumor expression of selected signaling pathways 
components with sunitinib PFS.
Results: 123 patients were analyzed (97 LR, 26 PR). In the LR cohort, overall 
response rate was 79% and median duration of best response was 30 months. Median 
PFS and overall survival were 43.2 (95% confidence intervals[CI]:37.2-49.3) and 63.5 
months (95%CI:55.1-71.9), respectively. At baseline PR patients had a significantly 
lower proportion of nephrectomies, higher lactate dehydrogenase and platelets 
levels, lower hemoglobin, shorter time to and higher presence of metastases, and 
increased Fuhrman grade. Higher levels of HEYL, HEY and HES1 were observed in 
LR, although only HEYL discriminated populations significantly (AUC[ROC]=0.704; 
cut-off=34.85). Increased levels of hsa-miR-27b, hsa-miR-23b and hsa-miR-628-5p 
were also associated with prolonged survival. No statistical significant associations 
between hsa-miR-23b or hsa-miR-27b and the expression of c-Met were found.
Conclusions: Certain mRCC patients treated with sunitinib achieve extremely 
long-term responses. Favorable baseline hematology values and longer time to 
metastasis may predict longer PFS. HEYL, hsa-miR-27b, hsa-miR-23b and hsa-miR-
628-5p could be potentially used as biomarkers of sunitinib response.
INTRODUCTION
Over the past years multiple molecularly targeted 
agents for the treatment of advanced renal cell carcinoma 
(RCC) have been developed, greatly improving clinical 
benefit to patients [1].
Sunitinib, a multitargeted tyrosine kinase inhibitor, 
was approved worldwide as a first-line treatment for 
selected clear-cell metastatic RCC (mRCC) patients. 
Sunitinib efficacy was established in a pivotal Phase 
3 study comparing sunitinib and interferon-α as first-
line treatment in 750 patients with mRCC, showing a 
significantly higher objective response ratio (47% vs 12%, 
respectively; P<0.001), significantly longer progression-
free survival (PFS) (median: 11 vs 5 months; Hazard 
ratio[HR]=0.539; 95% confidence intervals [CI]:0.451, 
0.643; P<0.001), and longer overall survival (OS) 
(median: 26.4 vs 21.8 months; HR=0.82; 95%CI:0.67, 
1.00, P=0.051) in the sunitinib group [2]. However, 9-21% 
of patients treated with sunitinib exhibit progressive 
disease as best response.
Similar to other conventional and molecular-
targeted antitumor agents, there is an interindividual 
variability in response to sunitinib treatment. Potential 
serum-, radiological-, clinical- and tissue-based predictive 
biomarkers have been investigated across multiple agents 
[3–5], obtaining promising results. Additionally, certain 
adverse events (AEs) (i.e. Hypertension, Hypothyroidism) 
induced by sunitinib in mRCC patients may be associated 
with an improvement in clinical outcomes [6, 7].
Inherited genetic variability may be one of several 
contributing tumor- and host-related factors underlying 
individual treatment response. Specific signaling pathways 
such as Notch [8], Hedgehog [9] and Wingless (Wnt)-
β-catenin [10] are critical for embryonic development, 
and for self-renewal and differentiation in adult stem 
cells, being also involved in tumor development and 
maintenance [11]. Remarkably, they are also involved 
in normal and pathological angiogenesis and, thus, have 
been considered as indicators of response to specific 
antiangiogenic therapies.
The microRNAs (miRNAs) are key regulators of 
oncogenic processes [12], representing a promising novel 
group of biomarkers. They are essential modulators of the 
above commented developmental signaling pathways, and 
are also involved in cancer stem cell maintenance [13].
The efficacy and safety of sunitinib in a subset 
of long-term responders has been previously described 
in retrospective pooled cohorts [14–16], although a 
comparison of extreme responders and non-responders is 
unpublished.
In the present analysis, we compared the baseline 
clinical characteristics and the levels of expression of 
various genes and miRNAs involved in Notch, Hedgehog, 
Wnt, hypoxia, epithelial mesenchymal transition and 
stem cell maintenance signaling in two extreme groups 
of patients: those with the highest benefit (long-term 
responders, LR) and those resistant to sunitinib (primary 
refractory, PR). We also explored the occurrence of several 
AEs as potential biomarkers of sunitinib efficacy.
RESULTS
Clinical characteristics
One hundred and twenty-three patients from 16 
Spanish centers were included, of which 97 (79%) were 
LR and 26 (21%) were identified as PR. In the LR cohort, 
partial response was achieved in 59% of patients, complete 
response in 21% of patients and SD in 21%. Median 
duration of best response was 29 months and 33 months in 
partial and complete responders, respectively. At the time 
of analysis 51 patients had progressed. Median PFS was 
43.2 months (95%CI: 37.2-49.3). Median OS was 63.5 
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months (95%CI: 55.1-71.9). In the PR cohort, median 
PFS and OS were 2.8 (95%CI: 2.5-3.1) and 7.0 months 
(95%CI: 3.3-10.7), respectively.
Baseline clinical characteristics that were 
significantly different between PR and LR patients are 
depicted in Table 1. In the overall population, 94% of 
patients had clear-cell histology with 7 patients having 
mixed histology (clear-cells plus sarcomatoid/papilar). 
Fourteen patients (11%) received sunitinib after cytokines 
and 109 patients (89%) in first-line, with no significant 
differences between groups.
Sunitinib was administered once-daily at either a 
starting dose of 50 mg (93% of patients), 37.5 mg (5%) or 
25 mg (2%) following 4-weeks-on/2-weeks-off schedule. 
The initial dose was reduced in 73% of patients (84% 
in LR group, 32% in PR group; P<0.001), mainly due 
to toxicity (92% of reductions). At the time of the study 
the alternative schedule 2 weeks-on/1 week-off was not 
established in clinical practice to manage toxicity.
Heng prognostic criteria were not significantly 
correlated with response in our population (P=0.109). 
However, most of the components individually, except for 
Table 1: Demographic and clinical characteristics
Baseline patient 
characteristics LR (n=97) PR (n=26) P-value
ECOG PS, N (%) 0 44 (55.0) 5 (23.8) <0.01
1 34 (42.5) 13 (61.9)
2 0 (0) 3 (14.3)
Nephrectomy, N (%) No 2 (2.1) 4 (15.4) <0.01
Yes 94 (97.9) 22 (84.6)
LDH, UI/L, mean (95%CI)
258.4
(235.9-281.0)
380.3
(317.1-443.6)
<0.001
Hemoglobin, g/dl, mean (95%CI)
13.81
(13.46-14.17)
11.96
(11.07-12.86)
<0.001
Platelets, 103/mm3, mean (95%CI)
240.6
(223.6-257.6)
368.6
(303.7-433.6)
<0.001
Time from primary to metastatic diagnosis, 
months, median (range) 24.7 (2.2 to 68.1) 2.5 (0.0 to 15.8) <0.01
Time from diagnosis to treatment onset, months, 
median (range) 28.7 (6.8 to 71.9) 3.8 (1.2 to 23.0) <0.01
Metastasis at diagnosis, 
N (%) No 63 (69.2) 12 (46.2) <0.05
Yes 28 (30.8) 14 (53.8)
Lung metastasis, N (%) 59 (60.8) 23 (88.5) <0.01
Brain metastasis, N (%) 3 (3.1) 4 (15.4) <0.05
Hepatic metastasis, N (%) 7 (7.2) 6 (23.1) <0.05
Fuhrman grade Grade 1 7 (10.3) 0 (0) <0.05
Grade 2 21 (30.9) 4 (23.5)
Grade 3 30 (44.1) 5 (29.4)
Grade 4 10 (14.7) 8 (47.1)
Heng risk factors, N (%) 0 22 (23.7) 2 (8.7) <0.01
1 49 (52.7) 7 (30.4)
2 18 (19.4) 11 (47.8)
3 4 (4.3) 3 (13.0)
ECOG-PS: Eastern Cooperative Oncology Group Performance Status; LR: long-term responders; PR: primary refractory; 
LDH: lactate dehydrogenase; CI: confidence intervals.
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calcium and neutrophil levels, showed significant differences 
between both cohorts, and 61% of PR patients presented ≥2 
Heng risk factors compared to 24% in LR group.
Molecular assessment
Fifty-two primary clear-cell primary tumor samples 
corresponding to 39 LR (75%) and 13 PR patients (25%) 
were analyzed. Among the different genes analyzed, 
only HES1, HEY and HEYL, putative effectors of Notch 
signaling, showed increased expression in the LR 
group compared to PR group (Figure 1A, 1B, and 1C, 
respectively; Figure 2). A significant positive internal 
correlation between the expression of these 3 genes was 
also observed (Figure 1D, and data not shown).
After the ROC analyses, only HEYL levels 
discriminated the studied populations with significant 
sensitivity and specificity (AUC=0.704). These analyses 
also provided a possible cut-off value of 34.85 (reference: 
GUSB). Of note, when the patients were classified 
according to their HEYL levels using this cut-off, an 
increased disease-specific survival in the high expression 
group was observed (Figure 1E).
Since HEYL is considered an effector of Notch 
signaling, we monitored whether LR and PR tumors 
displayed activated Notch. The expression of intracellular 
Notch domain (Notch-IC) and HEYL was determined in 
a TMA containing the previously analyzed samples. The 
samples were classified as negative or positive given their 
relatively small number (representative examples provided 
in Figure 1F). No statistically significant relationship 
between Notch-IC and HEYL positive staining was found 
(P=0.426) (Figure 1F).
Figure 1: HEYL expression is associated with LR population. (A-C) RTqPCR analyses showing the expression of HES1 (A), 
HEY (B) and HEYL (C) genes in LR and PR populations. Statistical significance was obtained by Mann–Whitney’s test *P-value ≤0.05; 
** P-value ≤0.01, *** P-value ≤0.005. (D) Correlation between the HES1 and HEYL expression values. P-value was estimated by Pearson 
correlation. (E) Kaplan-Meier analysis showing that high HEYL levels were associated with increased survival (P-value was obtained by 
the log-rank test). (F) Representative immunohistochemistry images Notch intracellular domain (NotchIC) and HEYL positive and negative 
tumors, and contingency tables showing the absence of significant association between NotchIC and HEYL. RTqPCR: Quantitative real-time 
reverse transcription polymerase chain reaction; LR: long-term responders; PR: primary refractory; CI: confidence intervals; m: months.
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Figure 3: miRNA expression is associated with LR population. (A-C) RTqPCR analyses showing the expression of miR-23b 
(A), miR-27b (B) and miR-628-5p (C) in LR and PR populations. Statistical significance was obtained by Mann–Whitney’s test ** P-value 
≤0.01. (D, E) Kaplan-Meier analysis showing that high levels of miR-628-5p (D) and miR-27b (E) were associated with increased survival 
(p value was obtained by the log-rank test). (F) Representative immunohistochemistry images of positive and negative tumors for total 
C-Met and phosphorylated (in Tyr1234 and Tyr1235) c-Met, and contingency tables showing the absence of significant association between 
high levels of miR-23b and miR-27b and reduced c-Met staining. RTqPCR: Quantitative real-time reverse transcription polymerase chain 
reaction; LR: long-term responders; PR: primary refractory; CI: confidence intervals; m: months.
Figure 2: RTqPCR analyses showing the expression of quoted genes in LR and PR populations. RTqPCR: Quantitative 
real-time reverse transcription polymerase chain reaction; LR: long-term responders; PR: primary refractory.
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MicroRNA assessment
Increased levels of 3 out of 13 studied miRNA were 
found in the LR population: hsa-miR-27b, hsa-miR-23b and 
hsa-miR-628-5p (Figure 3A, 3B, 3C; Figure 4). Additionally, 
the increased expression of these miRNAs was also 
associated with prolonged survival (AUC [ROC]=0.799; 
0.793 and 0.800, respectively; cut-off values: 0.60; 0.15 and 
0.005, respectively) (Figure 3D, 3E, and data not shown).
No validated targets have been yet identified for 
hsa-miR-628-5p. Both hsa-miR-27b and hsa-miR-23b 
inhibit the expression of c-Met and Notch1. A tendency of 
decreased c-Met activation in the LR group was observed, 
although statistical significance was not reached. Moreover, 
we did not find any association between increased levels 
of hsa-miR-23b or hsa-miR-27b, or the reduced levels of 
both, and the expression of c-Met (Figure 3F).
Correlation between PFS and toxicity in LR 
group
Ninety-four percent of LR patients presented at 
least one AE during the study, being the most common 
(all grades): asthenia (83%), mucositis (75%) and 
hand-foot syndrome (64%), followed by hypertension, 
hypothyroidism, neutropenia and thrombocytopenia 
(57%, 46%, 43% and 42%, respectively). A marked 
tendency towards prolonged PFS was observed in patients 
with hypertension or hypothyroidism, but did not reach 
statistical significance (Figure 5).
DISCUSSION
The results of this molecular study suggest that there 
is a potential correlation between Notch activation and long-
term response in mRCC patients treated with sunitinib. This 
correlation has been previously reported [17] and is aligned 
with the widely reported role of this pathway in angiogenesis 
[18, 19]. Our data also support that other relevant signaling 
pathways, such as Hedgehog and hypoxia, are not major 
players in sunitinib response in mRCC.
According to our analyses, only HEYL expression 
could be potentially used a biomarker of sunitinib 
response. Increased HEYL expression has been associated 
with neovascularization in breast cancer [20]. Nonetheless, 
other potential Notch signaling effectors, such as HES1 
and HEY, did not reach the statistical significance as 
unique biomarkers. Moreover, JAG1 levels did not 
discriminated studied populations, and Notch IC was not 
associated with increased HEYL levels. In our opinion, 
the low number of available tumor samples and the high 
intratumor heterogeneity in mCRR [21] may be limiting 
these results. Notch signaling is a complex process 
involving multiple cell compartments and proteins, and 
its possible role in sunitinib response requires further 
investigation in a larger cohort.
Various miRNAs can regulate hypoxia and 
angiogenesis [22], suggesting a potential role in patient’s 
response to antiangiogenic drugs. For instance, hsa-
miR-221/222, hsa-miR-141, hsa-miR-942, hsa-miR-
133a and hsa-miR-484 have been previously suggested 
as candidates for poor response to sunitinib [23–26]. 
However, there are important discrepancies among these 
studies, which are also limited by the small number of 
patients included and their specific clinical and therapeutic 
response characteristics. The results herein presented, 
comparing extreme groups of responders to sunitinib, do 
not support the potential significance of these pre-specified 
miRNAs. Here we provide evidence that changes in hsa-
miR-628-5p are distinctive of LR and PR populations 
of sunitinib-treated mRCC patients. This miRNA was 
previously identified by Prior et al [25]. Nonetheless, the 
absence of bona fide characterized targets of hsa-miR-628-
5p precludes ulterior functional analysis.
Figure 4: RTqPCR analyses showing the expression of quoted miRNAs in LR and PR populations. RTqPCR: Quantitative 
real-time reverse transcription polymerase chain reaction; LR: long-term responders; PR: primary refractory.
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Figure 5: Progression-free survival in the long-term responders’ cohort according to the occurrence of (A) hypertension; (B) hypothyroidism. 
Kaplan-Meier estimates. PFS: progression-free survival; CI: confidence intervals.
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To the best of our knowledge, this is the first report 
showing an association between increased levels of hsa-
miR-23b and hsa-miR-27b and prolonged response to 
sunitinib in patients with mRCC. However, their roles 
in other cancer types and in chemoresistance have been 
previously reported [27, 28]. The joint inhibition of the 
expression of Notch1 and c-Met by hsa-miR-23b and 
hsa-miR-27b reinforces our above commented hypothesis 
regarding the potential involvement of Notch signaling 
in sunitinib response, and warrants future research on 
this pathway. Furthermore, MET expression has been 
associated with resistance to sunitinib and with more 
aggressive tumor behavior in renal cancer, becoming an 
attractive target for the treatment of sunitinib-resistant 
mRCC patients [29]. However, we did not find a 
significant association between increased levels of hsa-
miR-23b or hsa-miR-27b or the reduced levels of either 
miRNAs with the expression or activity of MET in renal 
cancer samples. Further studies are needed to elucidate the 
possible targets of these two miRNAs regarding sunitinib 
response in mRCC patients.
Additionally, despite the strong tendency observed, 
we did not found a significantly prolonged PFS in our 
cohort of LR patients presenting sunitinib-related AEs, 
contrary to previous studies [6, 7], probably due to their 
extremely prolonged survival time.
We observed a significantly higher number of 
Heng risk factors [30] in PR patients, although risk 
categories did not differ between groups, probably related 
with the low number of patients included in PR group. 
Additionally, we found a significantly lower proportion 
of nephrectomies, higher lactate dehydrogenase levels, 
shorter time to metastatic disease, higher presence of 
lung, brain and hepatic metastasis, and increased Fuhrman 
grade among PR patients. Some of these factors have 
been previously identified as predictive of a shorter PFS 
[14, 16], while others may have arose given the extreme 
differences of the studied populations. The validation 
of its prognostic value in a large independent cohort is 
warranted.
In conclusion, our data present important molecular 
implications regarding the response to sunitinib in mRCC 
patients. However, given the lack of identified molecular 
targets and current limitations of immunohistochemistry 
techniques, we were unable to identify which pathways 
are conditioning sunitinib response. The identification 
of these pathways and the confirmation of HEYL, hsa-
miR-27b, hsa-miR-23b and hsa-miR-628-5p as predictive 
biomarkers will allow clinicians to offer an accurate and 
personalized treatment for both newly diagnosed and non-
responder patients in daily clinical practice.
Table 2: Sequences of the specific RT primer oligonucleotides used in the reverse transcription polymerase 
chain reaction
GENE RT Forward Reverse
Hu-cMyc GTTGAAGGAATCG AATGAAAAGGCCCCCAAGGTAGTTATCC GTCGTTTCCGCAACAAGTCCTCTTC
Hu-ACTB GCATTACATAATTTACAC CCAACCGCGAGAAGATGA TCCATCACGATGCCAGTG
Hu-TBP GTG TTT AAA ATC TAC ATA AGTGAAGAACAGTCCAGACTG CCAGGAAATAACTCTGGCTCAT
Hu-GUSB CTTCTGATACTTCTTATAC CGCCCTGCCTATCTGTATTC TCCCCACAGGGAGTGTGTAG
Hu-GAPDH TACTTTATTGATGGTACA AGCCACATCGCTCAGACAC GCCCAATACGACCAAATCC
Hu-PPIA1 AATGGTGATTCTTCTTGCTGG ATGCTGGACCCAACACAAAT TCTTTCACTTTGCCAAACACC
Hu-RPS13 CTTAATTAAATGGTAGAGATC GGTTGAAGTTGACATCTGACGA CTTGTGCAACACCATGTGAAT
Hu-VHL CCCTGACTGACTGAAGGCT ATCCGTAGCGGTTGGTGA CTCACGGATGCCTCAGTCTT
Hu-Hif1a CTGCATGATCGTC TTTTTCAAGCAGTAGGAATTGGA GTGATGTAGTAGCTGCATGATCG
Hu-Hif2 TAGGTGAACTTCATGTCC TACAAGGAGCCCCTGCTGTC TGCTGGATTGGTTCACACATG
Hu-Gli1 TGACTTCTGTCCCCACACTG AGCGCCCAGACAGAGTGT GGGGTCATCGAGTTGAACAT
Hu-Gli2 AGCTGGCTCAGCATGGTC ACTCCACACACGCGGAAC CCACTGAAGTTTTCCAGG
Hu-BMP4 TCCACAGCACTGGTCTTGAG TGGGATGTTCTCCAGATGTTCT GGGATGCTGCTGAGGTTAAA
Hu-PTCH1 CGAGGTTCGCTGCTTTTAAT TCTGGAGCAGATTTCCAAGG TTTGAATGTAACAACCCAGTTTAAATA
Hu-HES1 GTGCGCACCTCGGTATTAAC GAAGCACCTCCGGAACCT GTCACCTCGTTCATGCACTC
Hu-HEY AGCAGATCCCTGCTTCTCAA CGAGCTGGACGAGACCAT GGAACCTAGAGCCGAACTCA
Hu-HEYL GGGCATCAAAGAATCCTGTC GTCCCCACTGCCTTTGAG ACCGTCATCTGCAAGACCTC
Hu-AXIN2 CTTCATCCTCTCGGATCTGC GCTGACGGATGATTCCATGT ACTGCCCACACGATAAGGAG
Hu-SUFU ACTGCAGGGCCCA TGTTGGAGGATTTAGAAGATTTGAC AGGCCAGCTGTACTCTTTGG
Hu-JAG1 TTGATCATGCCCGA GGCAACACCTTCAACCTCA GCCTCCACAAGCAACGTATAG
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PATIENTS AND METHODS
Patients
Eligibility criteria included adult (age ≥18 
years) patients with confirmed mRCC with a clear-cell 
component treated with sunitinib. Patients were classified 
in two groups:
• Long-term responders: patients who achieved 
a PFS ≥22 months and at least complete response (CR), 
partial response or stable disease (SD).
• Primary refractory: patients who showed 
progressive disease in the first 3 months after sunitinib 
onset.
Study design and assessments
Retrospective, observational, multicenter study of 
two extreme groups of patients (LR and PR) treated with 
sunitinib under clinical practice. The study was conducted 
between January 2012 and January 2014 in 16 centers 
participating in the Spanish Oncology Geniturinary 
Group (SOGUG). The objectives were to identify baseline 
clinical factors associated with long-term clinical benefit 
to sunitinib treatment and to correlate tumor expression 
of different signaling pathways components and the 
occurrence of treatment-related AEs with treatment 
associated survival.
This study was carried out in accordance with the 
declaration of Helsinki and approved by the Spanish 
Authorities and Ethics Committees of each participating 
hospital. All patients gave written informed consent.
Study procedures
Immunohistochemistry and genetic analyses were 
carried out in available archived formalin-fixed paraffin 
embedded (FFPE) clear-cell primary tumor samples. 
Hematoxylin and eosin stained sections of the tumor 
samples were examined by a pathologist to confirm the 
diagnosis and estimated tumor content. These analyses 
were performed at the Molecular Laboratory of Hospital 
12 de Octubre (Madrid, Spain).
The following patient characteristics and outcome 
data were collected using uniform data collection 
templates: Date of birth, gender, age at CRC diagnosis, 
date of first diagnosis of tumor disease, baseline TNM, 
baseline cancer stage, histological subtype, Furhman 
grade, comorbidities, nephrectomy (yes/no), nephrectomy 
type (total/partial), percentage of tumor necrosis, 
Karnofsky/ECOG performance status, baseline lactate 
dehydrogenase level, baseline corrected calcium level, 
baseline hemoglobin level, left ventricular ejection 
fraction, presence of thrombocytosis at baseline, presence 
of neutrophilia at baseline, baseline Heng risk factors, 
previous radiotherapy received (yes/no), number of 
metastatic locations, recurrence (metastatic) location and 
date, and treatments received (dates, type, doses, associated 
toxicity and response [PFS, time to progression and OS]).
Quantitative real-time reverse transcription 
polymerase chain reaction (RT-qPCR)
Expression levels of 13 selected miRNAs (miR-
942, miR-628-5p, miR-133a, miR-484, miR-141, miR-
23a, miR-23b, miR-27b, miR-21, miR-200a, miR-200c, 
miR-141and miR-155) and mRNAs (MYC, VHL, HIF1A, 
HIF2, GLI1, GLI2, BMP4, PTCH1, HES1, HEY, HEYL, 
AXIN2, SUFU and JAG1 were monitored by RT-qPCR 
in both groups. The miRNA were selected on the basis 
of their involvement in angiogenesis, modulation of the 
Notch, Hedgehog and/or Wnt signaling pathways, or 
by being previously reported as biomarkers of Sunitinb 
response in renal cancer samples [23–26]. For the mRNA 
normalization six previously reported genes were assayed 
(ACTB, TBP, GusB, GAPDH, PPIA1 and RPS13) and 
evaluated using three normalizer evaluation software 
(GeNorm, NormFinder and BestKeeper). The best 
normalizer gene was GusB, so the expression analyses 
were performed relative to this gene.
Total RNA was isolated from ten 10 μm sections 
of each tumor sample and using miRNeasy FFPE Kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s 
recommendations. Reverse transcription was performed 
using the Omniscript RT Kit (Qiagen, Hilden, Germany), 
using 50 ng of total RNA and a mix of 10 mM of all specific 
RT primers (Table 2) in 50 μl final volume. Polymerase 
chain reaction (PCR) was performed in a 7500 Fast Real 
Time PCR System using Go Taq PCR master mix (Promega, 
Fitchburg, WI, USA) and 1 μl of cDNA as a template. 
Melting curves were performed to verify specificity 
and absence of primer dimers. Reaction efficiency was 
calculated for each primer combination. The sequences 
of the specific qPCR oligonucleotides are shown in Table 
2. To measure quantitatively the expression of miRNAs, 
RNA was extracted using the same method as for the genes. 
Reverse transcription was carried out from 10 ng total 
RNA along with miR-specific primer using the TaqMan® 
MicroRNA Reverse Transcription Kit (Applied Biosystems, 
Foster City, CA, USA). PCR assays were performed using 
TaqMan® Gene Expression Master Mix and 7500 Fast Real 
Time PCR System (Applied Biosystems, Foster City, CA, 
USA) as reported [31]. For miRNA normalization, we 
used RNU6B. The potential genes targeted by the studied 
miRNA were assessed using the miRTarBase webtool 
(http://mirtarbase.mbc.nctu.edu.tw/) [32].
Construction of tissue microarrays (TMA) and 
immunohistochemistry
The expression of Notch IC (MAB3647 R&D 
Systems, Minneapolis, MN, USA; 1/100 diluted), HEYL 
(TA324613, Origene 1/500 diluted), c-MET (AF276, 
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R&D Systems; 1/100 diluted) and c-MET phosphorylated 
in Y1234/Y1235 (AF2480, R&D Systems, 1/100 diluted) 
were assessed by immunohistochemistry in TMA after 
antigen retrieval treatment. Signal was amplified using 
avidin-peroxidase (ABC elite kit Vector, Burlingame, 
CA, USA) and visualized using diaminobenzidine as 
a substrate (DAB kit Vector, Burlingame, CA, USA). 
Scoring of the results and selection of the thresholds, 
internal controls for reactivity of each antibody, and tissue 
controls for the series were done by double blind method 
according previously published methods [33]. At least two 
representative duplicate cores for each case were scored.
Statistical analysis
Protein, mRNA and miRNA expression (positive 
vs negative) were correlated with treatment outcome 
according to the cohorts of LR and PR. Survival 
probabilities were assessed by the Kaplan-Meier method. 
Cox proportional hazard models were used to identify 
predictors of treatment outcomes. To determine their 
ability to discriminate the two populations we sequentially 
performed unpaired tTest, ROC analyses and Kaplan-
Meyer distributions with LogRank test. For all statistical 
tests, an a priori significant level of α=0.05 was assumed.
Efficacy end points included ORR, OS and PFS, 
assessed by investigators using Response Evaluation 
Criteria in Solid Tumours v1.1 [34]. The AEs were 
recorded regularly and graded according to Common 
Terminology Criteria for Adverse Events (CTCAE) v4.0. 
SPSS Statistics© software version 19 (IBM, Armonk, NY) 
was used for statistical analysis.
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